Roivant Sciences' (ROIV) Buy Rating Reaffirmed at HC Wainwright

Roivant Sciences (NASDAQ:ROIV - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They presently have a $18.00 price objective on the stock. HC Wainwright's price objective would suggest a potential upside of 70.49% from the company's previous close.

Separately, Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $17.93.

Roivant Sciences Stock Up 1.0 %

Shares of Roivant Sciences stock traded up $0.11 on Tuesday, hitting $10.56. The stock had a trading volume of 2,525,684 shares, compared to its average volume of 4,240,765. Roivant Sciences has a twelve month low of $9.76 and a twelve month high of $13.06. The business's 50 day moving average is $11.41 and its two-hundred day moving average is $11.59. The stock has a market cap of $7.69 billion, a price-to-earnings ratio of 1.87 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.65% and a net margin of 3,827.42%. As a group, equities analysts predict that Roivant Sciences will post -1.19 earnings per share for the current fiscal year.

Insider Activity at Roivant Sciences

In other news, COO Eric Venker sold 100,000 shares of the business's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00. Following the transaction, the chief operating officer now owns 606,525 shares in the company, valued at $6,865,863. The trade was a 14.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sciences Ltd. Roivant purchased 16,845,010 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was bought at an average cost of $20.00 per share, for a total transaction of $336,900,200.00. Following the acquisition, the director now directly owns 96,650,341 shares in the company, valued at $1,933,006,820. This trade represents a 21.11 % increase in their position. The disclosure for this purchase can be found here. Insiders sold 1,942,629 shares of company stock valued at $23,034,486 in the last three months. Corporate insiders own 7.90% of the company's stock.

Institutional Investors Weigh In On Roivant Sciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. raised its holdings in Roivant Sciences by 478.6% during the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after acquiring an additional 1,948 shares during the period. Gladius Capital Management LP bought a new stake in Roivant Sciences during the 3rd quarter valued at $35,000. Aster Capital Management DIFC Ltd bought a new stake in Roivant Sciences during the 4th quarter valued at $39,000. US Bancorp DE raised its holdings in Roivant Sciences by 146.5% during the 3rd quarter. US Bancorp DE now owns 3,278 shares of the company's stock valued at $38,000 after acquiring an additional 1,948 shares during the period. Finally, GAMMA Investing LLC raised its holdings in Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock valued at $42,000 after acquiring an additional 1,288 shares during the period. Institutional investors own 64.76% of the company's stock.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.